November 12, 2014
Notes: Felix, Klaus
Research Support, Non-U.S. Gov’t
PLoS One. 2013 Dec 9;8(12):e82755. doi: 10.1371/journal.pone.0082755. eCollection 2013.
Author Address: Department of General Surgery, University of Heidelberg, INF 110, Heidelberg, Germany.
Functional Proteome Analysis, German Cancer Research Center (DKFZ), INF 580, Heidelberg, Germany.
Infection and Cancer Program, German Cancer Research Center (DKFZ), INF 260, Heidelberg, Germany.
Reference Type: Journal Article
Record Number: 4661Author: Fitzgibbons, T. P., Paolino, J., Dagorn, J. C. and Meyer, T. E.
Title: Usefulness of pancreatitis-associated protein, a novel biomarker, to predict severity of disease in ambulatory patients with heart failure
Journal: Am J Cardiol
Date: Jan 1
Short Title: Usefulness of pancreatitis-associated protein, a novel biomarker, to predict severity of disease in ambulatory patients with heart failure
Alternate Journal: The American journal of cardiology
ISSN: 1879-1913 (Electronic)
Accession Number: 24188888
Cause of Death/trends
Predictive Value of Tests
Severity of Illness Index
Tumor Markers, Biological/*blood
Abstract: Pancreatitis-associated protein (PAP) is a novel cytokine with putative anti-inflammatory effects. PAP gene expression has been found to be increased in the myocardium of rats with decompensated pressure-overload hypertrophy. A prospective pilot study was performed to test the hypotheses that PAP is elevated in ambulatory patients with heart failure (HF) and that concentrations correlate with the severity of disease. Blood samples were obtained from patients with HF (n = 70) and normal controls (n = 17). Patients with New York Heart Association class III and IV symptoms had a greater mean PAP than patients with class I and II symptoms (35.5 +/- 4.0 vs 10.3 +/- 1.0 mug/L, p <0.001) and normal controls (35.5 +/- 4.0 vs 6.2 +/- 0.5 mug/L, p <0.001). Receiver-operating characteristic curves revealed that PAP had similar sensitivity and specificity for HF admission at 6 months as B-type natriuretic peptide and equivalent predictive value for 12-month and 24-month all-cause mortality. On the basis of the receiver-operating characteristic curve analysis, patients were then grouped into those with a serum PAP <24 or >/=24 mug/L. Patients with PAP >/=24 mug/L had significantly worse renal function, greater B-type natriuretic peptide and C-reactive protein levels, higher pulmonary artery systolic pressure, and greater 6- and 24-month all-cause mortality (p <0.05). In conclusion, PAP levels correlate with disease severity in patients with HF and are a marker of cardiorenal syndrome, neurohormonal activation, and elevated filling pressures. PAP is a sensitive and specific marker for increased 6-month HF morbidity and 12- and 24-month all-cause mortality. These results justify the prospective evaluation of PAP as a novel prognostic marker for disease severity in patients with HF.